LØLene Sofie Granfeldt Østgård

Lene Sofie Granfeldt Østgård

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lene Sofie Granfeldt Østgård has a total of 90 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Changes in intensive care unit admission rates, organ support, and mortality in patients with acute myeloid leukaemia over a 12‐year period: a Danish nationwide cohort study

    by Cecilie V. Maeng, Lene Sofie G. Østgård, Christian F. Christiansen, Kathleen D. Liu

    Changes in acute myeloid leukaemia (AML) treatment may affect requirement for admission to and treatments in intensive care units (ICUs). We evaluated trends in ICU admission, use of organ support, and 1-year mortality in Danish AML patients. Of 1417 AML patients diagnosed 2005-2016, 28.0% (n=397) were ICU-admitted within 3 years, with no major change in admission rate during the 12-year period. Use of mechanical ventilation and dialysis decreased (66.7% to 40.6%), while use of non-invasive ventilation increased (20.0% to 50.0%). Concurrently, 1-year mortality declined among all patients (36.0% in 2005 to 28.8% in 2016) and ICU-admitted patients (80.0% to 65.6%).


  • Open Access

    Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients

    by Andreas K. Øvlisen, Lasse H. Jakobsen, Kristian H. Kragholm, René E. Nielsen, Martin Hutchings, Rasmus B. Dahl‐Sørensen, Henrik Frederiksen, Danny Stoltenberg, Martin Bøgsted, Lene S. G. Østgård, et al.

    Cancer‐related psychological distress may lead to depression and anxiety among survivors. The vast majority of patients with Hodgkin lymphoma (HL) become long‐term survivors, but the risk of mental health problems after HL is not well‐characterized. Using national population‐based registries, we investigated the cumulative incidence of psychotropic drug (antidepressants, antipsychotics, and anxiolytics) use (proxies for depression and anxiety) in HL patients as well as if an increased risk would normalize over time for patients in remission. The study included 945 HL patients aged 18‐92 years and 4725 matched persons. In total, 215 HL patients (22.8%) received a prescription of any psychotropic drug (PD) at some point after date of diagnosis compared to 545 persons (11.5%) in the matched cohort. Cumulative incidences with death/relapse as competing risk confirmed that HL patients were at higher risk of receiving psychotropic drug prescriptions, but the increased risk was transient and normalized to the matched population 5 years into survivorship. Increased age, Eastern Cooperative Oncology Group performance status, and disease stage were associated with higher risk of psychotropic drug prescriptions. Given the increased rate of psychotropic drug prescriptions after HL diagnosis, screening for symptoms of depression and anxiety is warranted after HL diagnosis and first years into survivorship.


  • Open Access

    Longer distance to specialized treatment centers does not adversely affect treatment intensity or outcomes in adult acute myeloid leukemia patients. A Danish national population-based cohort study

    by Michael Tøstesen, Mette Nørgaard, Jan Maxwell Nørgaard, Bruno C Medeiros, Claus Werenberg Marcher, Ulrik Malthe Overgaard, Marianne Tang Severinsen, Claudia Schoellkopf, Lene Sofie Granfeldt Østgård

    Background: Treatment of acute myeloid leukemia (AML) is widely centralized. Longer distances to a specialized treatment center may affect patients’ access to curative-intended treatment. Especially during outpatient treatment, distance may also affect survival. Methods and patients: The authors conducted a national population-based cohort study including all AML patients diagnosed in Denmark between 2000 and 2014. We investigated effects of distance (100) to the nearest specialized treatment facility on the probability of receiving intensive chemotherapy, HSCT, and achieving a complete remission (CR) using logistic regression analysis (odds ratios; ORs). For overall survival, we used Cox proportional hazards regression (hazard ratios [HRs]) and adjusted (a) for relevant baseline characteristics. Results: Of 2,992 patients (median age=68.5 years), 53% received intensive chemotherapy and 12% received low-dose chemotherapy outpatient regimens. The median distance to a specialized treatment center was 40 km (interquartile range=10–77 km). No impact of distance to specialized treatment centers was seen on the probability of receiving intensive chemotherapy (10–25 km, aOR=1.1 (CI=0.7–1.7), 25–50 km, aOR=1.1 (CI=0.7–1.7), 50–100 km, aOR=1.3 (CI=0.9–1.9), and >100 km, aOR=1.4 [CI=0.9–2.2]). Overall survival in patients regardless of therapy (100 km, aOR=1.0 [CI=0.9–1.2]), in intensive therapy patients, or in patients’ choice of post-remission was not affected by distance to specialized treatment center. Distance to a transplant center also did not affect the probability of HSCT or survival post-HSCT. Conclusion: In Denmark, distance to a specialized treatment facility offering remission-induction chemotherapy and HSCT does not negatively affect access to curative-indented therapy, treatment-response, or survival in AML patients.


  • Addressing the room for improvement in management of acute promyelocytic leukemia

    by Jan M. Nørgaard, Lone S. Friis, Jørgen S. Kristensen, Marianne T. Severinsen, Ingolf Mølle, Claus W. Marcher, Peter Møller, Claudia Schoellkopf, Ove J. Nielsen, Birgitte S. Preiss, et al.

    Acute promyelocytic leukemia (APL) is highly curable. To achieve high cure rates, targeted therapy with retinoic acid (ATRA) must be started promptly at time of suspected diagnosis. Early death rates (EDRs, ≤30 days from diagnosis) differ markedly in patients treated on clinical trials compared to the general population.Objectives and methods: We used the comprehensive Danish National Acute Leukemia Registry (DNLR) to investigate the incidence, treatment, EDR, and long‐term clinical outcome in APL between 2000 and 2014.Results: Twenty‐two of 41 deaths occurring in 122 APL patients were EDs which were primarily caused by intracranial hemorrhage, disseminated intravascular coagulation (DIC), sepsis, and multiorgan failure. The overall EDR was 18.0%, whereas clinical trial participants had an EDR of 6.7%. Fifteen patients recruited to the NCRI AML17 APL trial from 2010 to 2013 were younger and had decreased mortality (HR 0.18, CI 0.04‐0.86, P = 0.02) compared to contemporarily treated patients (n = 15) not recruited to a clinical trial. Performance status, leukemia origin, and Sanz‐score were independent prognostic variables.Conclusions: The very low EDR for on‐trial patients is not observed in the general cohort of APL patients. Diagnostic awareness emerges as the greatest clinical challenge in management of APL.


  • Open Access

    NSAID consumption and risk of acute myeloid leukemia: a national population-based case-control study

    by Lene Sofie Granfeldt Østgård, Mette Nørgaard, Lars Pedersen, René Østgård, Lone Smidstrup Friis, Claudia Schöllkopf, Marianne Tang Severinsen, Claus Werenberg Marcher, Bruno C Medeiros, Morten Krogh Jensen

    Background: Most cases of acute leukemia arise without identifiable risk factors. Studies investigating the impact of autoimmune diseases and infections on leukemogenesis have revealed conflicting results. If inflammation increases the risk of acute myeloid leukemia (AML), ­nonsteroidal anti-inflammatory drug (NSAID) use may decrease the risk of leukemia. Methods: We conducted a case-control study of 3,053 patients with AML diagnosed between 2000 and 2013, who were registered in the Danish National Acute Leukemia Registry, and 30,530 population controls matched on sex and age. We identified prescriptions through the Danish National Health Service Prescription Database. We used conditional logistic regression analysis to compute ORs associating AML with NSAID use overall, in patients with inflammatory diseases, and for specific AML subtypes (de novo AML, AML related to previous hematological disease, ie, secondary AML [sAML], or therapy-related AML [tAML; exposed to previous cytotoxic therapy]). Results: Overall, NSAID use was not associated with a lower risk of AML (OR 1.1, 95% CI=1.0–1.2), de novo AML (OR 1.0, 95% CI=0.9–1.1), and sAML/tAML (OR 1.3, 95% CI=1.1–1.5). In addition, in patients with known inflammatory diseases, NSAIDs did not affect AML risk (OR 0.9, 95% CI=0.5–1.6). Number of prescriptions, type of NSAID, age, or sex did not influence the results. Conclusion: In line with our recent findings that showed no association between autoimmune diseases and infections and de novo AML, NSAID use was not found to reduce the risk of AML.


  • Open Access

    Associations between cohabitation status, treatment, and outcome in AML patients: a national population-based study

    by Lene Sofie Granfeldt Østgård, Mette Nørgaard, Bruno C. Medeiros, Marianne Tang Severinsen, Lone Smidstrup Friis, Claus Werenberg Marcher, Claudia Schoellkopf, Jan Maxwell Nørgaard


  • Open Access

    Epidemiology and impact of preceding or underlying disease in secondary acute myeloid leukemia

    by Lene Sofie Granfeldt Østgård, Bruno C. Medeiros


  • Open Access

    Stringent or nonstringent complete remission and prognosis in acute myeloid leukemia: a Danish population-based study

    by Andreas K. Øvlisen, Anders Oest, Mette D. Bendtsen, John Bæch, Preben Johansen, Line S. Lynggaard, Ingolf Mølle, Thomas B. Mortensen, Duruta Weber, Gideon Ertner, et al.

    Key Points: sCR and non-sCR in acute myeloid leukemia are associated with different prognoses. Three lineage blood cell recoveries have independent impacts on prognosis.


  • Open Access

    Autoimmune diseases, infections, use of antibiotics and the risk of acute myeloid leukaemia: a national population‐based case‐control study

    by Lene S. G. Østgård, Mette Nørgaard, Lars Pedersen, René D. Østgård, Bruno C. Medeiros, Ulrik M. Overgaard, Claudia Schöllkopf, Marianne Severinsen, Claus W. Marcher, Morten K. Jensen

    Summary: Previous studies reported increased risk of acute myeloid leukaemia (AML) in individuals with inflammatory conditions. However, it is unclear whether this association is explained by preceding cytotoxic therapy or haematological diseases. We conducted a nationwide case‐control study that included 3053 AML patients, diagnosed in Denmark between 2000 and 2013, and 30 530 sex‐ and age‐matched population controls. We retrieved information on autoimmune disease, infections, and use of antibiotics and computed odds ratios for AML (conditional logistic regression). Results were stratified by AML type, sex, and age. Autoimmune diseases were associated with an overall increased risk of AML {odds ratio [OR] 1·3 [95% confidence interval (CI) = 1·1–1·5]}. However, the risk was confined to patients with previous haematological disease or cytotoxic therapy exposure [secondary/therapy‐related AML (sAML/tAML0) OR 2·0 (95% CI = 1·6–2·6)] and not de novo AML [OR 1·1 (95% CI = 0·9–1·3)]. Similarly, any prior infection requiring hospitalization was associated with a higher risk of AML [OR 1·3 (95% CI = 1·1–1·4)]. Again, this association was evident for sAML/tAML [OR 1·8 (95% CI = 1·5–2·2)], and not de novo AML [OR 1·1 (95% CI = 1·0–1·2)]. In conclusion, autoimmune diseases and infections were associated with an increased AML risk only in subjects with prior haematological disease and/or cytotoxic treatment. These observations suggest, that inflammation plays – if any – a minor role for the development of de novo AML.


  • Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study

    by Jorne Lionel Biccler, Lene Sofie Granfeldt Østgård, Marianne Tang Severinsen, Claus Werenberg Marcher, Peter Møller, Claudia Schöllkopf, Lone Smidstrup Friis, Martin Bøgsted, Lasse Hjort Jakobsen, Tarec Christoffer El-Galaly, et al.